

Date: July 21, 2026

To,
National Stock Exchange of India Limited
BSE Limited
Symbol: NSE: GRANULES: BSE: 532482

Dear Sir,

Sub: Presentation to the Analysts/Investors

We refer to the unaudited financial results for the first quarter of the FY 2026-2027, submitted to you today i.e., on July 21, 2026. We are now enclosing the presentation in this regard to the Analysts/Investors.

This is pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Kindly take the above information on record.

For GRANULES INDIA LIMITED

**CHAITANYA TUMMALA
(COMPANY SECRETARY &
COMPLIANCE OFFICER)**



REGISTERED OFFICE

Granules India Limited

CIN: L24110TG1991PLC012471

15th Floor, Granules Tower, Botanical Garden Road, Kondapur, Hyderabad – 500084, Telangana, India

Contact Us: Tel: +91 40 69043500 | Fax: +91-40-23115145 | mail@granulesindia.com

www.granulesindia.com

Where strategy meets
**Evolving Healthcare
Needs, Science & Sustainability.**



Granules India Limited

**Earnings Presentation
Q1 FY27**

21st July 2026

The Presentation is to provide the general background information about the Company's activities as at the date of the Presentation. The information contained herein is for general information purposes only and based on estimates and should not be considered as a recommendation that any investor should subscribe / purchase the company shares. The Company makes no representation or warranty, express or implied, as to, and does not accept any responsibility or liability with respect to, the fairness, accuracy, completeness or correctness of any information contained herein.

This presentation may include certain "forward looking statements". These statements are based on current expectations, forecasts and assumptions that are subject to risks and uncertainties which could cause actual outcomes and results to differ materially from these statements. Important factors that could cause actual results to differ materially from our expectations include, amongst others general economic and business conditions in India, ability to successfully implement our strategy, our research and development efforts, our growth and expansion plans and technological changes, changes in the value of the Rupee and other currencies, changes in the Indian and international interest rates, change in laws and regulations that apply to the Indian and global pharmaceuticals industries, increasing competition, changes in political conditions in India or any other country and changes in the foreign exchange control regulations in India. Neither the company, nor its directors and any of the affiliates or employee have any obligation to update or otherwise revise any forward-looking statements. The readers may use their own judgment and are advised to make their own calculations before deciding on any matter based on the information given herein.

No part of this presentation may be reproduced, quoted or circulated without prior written approval from Granules India Limited.

Dr. Krishna Prasad Chigurupati Chairman & Managing Director



“ Q1 FY27 marks an important step forward for Granules India as the foundations strengthened during FY26 begin to translate into greater execution confidence, strategic clarity and business resilience. Our focus remains firmly on regulatory and quality excellence, portfolio transformation toward complex and differentiated products, geographic and customer diversification and scaling new growth engines. While external cost pressures and supply chain volatility require continuous management for next couple of quarters, we are continuing to invest in R&D largely towards Complex Gx, digitalization, operational excellence, sustainability and talent to support long-term value creation. With a stronger organization, a more balanced portfolio and clear strategic priorities, we remain confident in Granules’ ability to deliver sustainable growth for all stakeholders. ”

Revenue

₹14,768 Mn

+22% YoY Growth

Margin %

65.6 %

+74 bps YoY

EBITDA

₹3,389 Mn

+37% YoY Growth

PAT

₹ 1,800 Mn

+60% YoY Growth

Q1FY27 Key Business Takeaways

Revenue up 22% YoY to ₹14,768 Mn with PAT +60% to ₹1,800 Mn and EBITDA +37% YoY

Complex Gx mix now 50% of FD portfolio lifted gross margin to 65.6% and EBITDA margin to 22.9% (+256 bps YoY)

Net Debt/EBITDA improved to 0.07x from 0.34x; ROCE up to 18.0% (~196 bps YoY) on ₹3,874Mn cash flow from operations

US products portfolio - Rank #1 in 10 products out of 35 (29%) and Top-3 in 18 products (50%) as per MAT May'26 underscoring deep market leadership

5 FD and 4 API filings in Q1FY27; R&D ₹880 Mn (6.0% of sales) seeding a high-value pipeline for future growth.

2nd sole First-to-File — Sodium Oxybate ER (~Brand value \$267M MAT Apr'26) plus 25 ANDAs under approval with market size of ~\$40Bn (Brand + Gx) as per May'26 MAT, powering a high-value next launch wave.

GPI received a VAI-classified and **received FDA EIR** for its April 2026 inspection

A man and a woman in white lab coats are standing in a laboratory, looking at a document held by the man. The woman is holding a pen and looking at the document. The background shows other people in lab coats working in the lab.

Quarterly Performance Q1 FY27

- Portfolio enrichment toward Complex Gx (50% of FD revenue, increased spending in complex pipeline) is strengthening quality of business.
- Strong EBITDA growth of 37% YoY, with capital discipline further supporting healthy free cash flow generation.

₹14,768 Mn

Revenue ₹12,101 (+22% YoY)

Revenue ₹14,706 (+0.4% QoQ)

65.6%

Gross Margin (+74 bps YoY)

Gross Margin (-11 bps QoQ)

₹3,389 Mn

EBITDA of 22.9%

+256 bps YoY

-99 bps QoQ

(Growth of +37% YoY, -4% QoQ)

₹1,800 Mn

PAT of 12.2%

Growth of +60% YoY
PBT before exceptional items growth
of +41% YoY, - 2% QoQ

18.0%

ROCE

(17.6% in FY26)

ROCE = Annualised EBIT / Average Capital Employed

Capital Employed = Total assets – Current liabilities excluding
short term borrowings – Cash & Bank Balances

0.07x

Net Debt/EBITDA

(0.34x in FY26)

Net Debt = Interest bearing borrowings – Cash & Bank Balance

29%

Net Working Capital to Sales

(30% in FY26)

NWC to Sales = Average (Current Assets – Current Liabilities)/
Revenue

Current Assets = Total Current Assets – Cash & Bank Balance
Current Liabilities = Total Current Liabilities – Short-term Borrowings

₹3,874 Mn

Cash Flow from Operations

₹1,003Mn in Q4FY26

₹2,806Mn in Q1FY26

Q1FY27 Financial Performance

Focused investments in Complex Gx R&D and talent are enhancing our future growth prospects while reinforcing the quality of earnings


Particular	Q1 FY27	Q1 FY26	Y-o-Y	Q4 FY26	Q-o-Q
Revenue	14,768	12,101	22%	14,706	0%
Gross Margin	9,690	7,850	23%	9,665	0%
% of Gross Margin	65.6%	64.9%	74 bps 	65.7%	-11 bps
Manpower Cost	2,546	2,028	26%	2,404	6%
R&D	880	678	30%	781	13%
Other Expenses	2,875	2,678	7%	2,958	-3%
EBITDA	3,389	2,467	37%	3,521	-4%
% of EBITDA	22.9%	20.4%	256 bps 	23.9%	-99 bps 
PBT (Before Exceptional items)	2,404	1,704	41%	2,464	-2%
Exceptional Items / (Income)	0	259		-159	
PAT	1,800	1,126	60%	2,016	-11%
% of PAT	12.2%	9.3%	288 bps 	13.7%	-152 bps

Peptides CDMO had an EBITDA loss of ₹124Mn in Q1FY27 as compared to positive EBITDA of ₹15Mn in Q4FY26 in line with project milestones services and projects


Revenue Diversification: Segments and Regions

- YOY Higher Revenue growth of Finished Dosages contributed by Complex Gx.
- YOY Higher growth in Europe and Rest of World are enabling us to maximize return on R&D capital.

Segments



Regions




YoY Growth	FD +22%	API +19%	PFI +9%	CDMO +106%
QoQ Growth	FD +2%	API -2%	PFI -3%	CDMO -14%





North America +13%	Europe +51%	ROW +56%
North America 0%	Europe -4%	ROW +11%

Segment	Definition
Integrated Gx	Products where API is key; API forward integrated to value added PFIs and FDs (mid to high volume) Value proposition: Backward integration/ Strategic tie ups Supply chain security and cost competitiveness
Complex Gx	Products with high entry barriers due to various reasons: • Complexity in formulation development and manufacturing • Complexity in API development • Complexity in IP/ BE strategy • Complexity in Compliance • Complexity in route of administration or drug-device combination
Others	Products that are time based/ opportunity products with an inherent capability of falling into the integrated basket.

Accelerated growth in Complex Gx products resulting in 50% share of FD from 39% YOY basis



Capital Efficiency and Allocation Discipline



Balance Sheet Strength continues

- Strong balance sheet and financial flexibility provide the capacity to fund growth and navigate market uncertainties.
- Improved working capital efficiency continues to support stronger cash generation and operating discipline.


CAPEX Discipline

- Capex moderated in Q1FY27 as the Genome Valley investment completed.
- Investment activity is expected to pick up gradually, driven by digitalization and modular growth projects at existing facilities


Return on Capital Employed (ROCE)

- ROCE improved to 18.0%, up ~196 bps YoY, driven by stronger profitability and an increasing contribution from the Complex Gx portfolio.
- Genome Valley and Peptide CDMO remain in the ramp-up phase, offering meaningful upside returns in the medium term

Quarterly P&L Performance Trend (Last 6 Quarters)




- **YOY 22%↑** Higher Revenue growth of Finished Dosages contributed by Complex Gx.
- YOY Higher growth in Europe and Rest of World are steadily diversifying the healthy revenue mix and return on capital.




Gross margin expanded around **74 bps ↑ YoY** to 65.6%, led by a higher contribution from Complex Gx.

Quarterly P&L Performance Trend (Last 6 Quarters)


R&D and % to sales



EBITDA and EBITDA %



PAT and PAT %



- R&D investment increased to 6% of sales, to support a differentiated, high-value pipeline and future growth opportunities.
- Multiple filings and approvals across key markets continue to strengthen the portfolio and launch pipeline.

- EBITDA grew **37% ↑ YoY**, with margin expanding **256 bps** to 22.9%.
- Growth was driven by a higher Complex Gx finished-dosage, increasing from 39% share of FD to 50% YoY.

PAT grew **60% ↑ YoY**, supported by margin expansion from improved product mix

A wide-angle photograph of a large, modern research laboratory. The room is filled with various scientific instruments, including large blue and white machines, likely for chromatography or mass spectrometry. Several scientists in white lab coats are working at different stations. Some are seated at desks with multiple computer monitors, while others are standing and operating equipment. The laboratory has a clean, professional appearance with white walls, glass partitions, and bright overhead lighting. The overall atmosphere is one of active research and collaboration.

R&D Capability

FD Portfolio Transformation: Scaling to Complex Gx

FTF

Sole First-To-File

Amphetamine Extended-Release Tablet

Sodium Oxybate Extended-Release Oral Suspension

R&D Pipeline Momentum

153 Total dossier Filed

100 Approved


3 Tentatively Approved

50 Awaiting Approval

61 Complex Gx Filed


Filed Dossiers Segmentation

■ Integrated Gx ■ Complex Gx ■ Others




Dossier Filing Trend

■ Integrated Gx ■ Complex Gx ■ Others




FD portfolio is progressing strategically up the complexity curve, indicating a purposeful move toward more sustainable value creation.

Dossier Filing Status by Market



Global DMF Filings (Total: 112)



Global Extensions of key complex molecules
Q1FY27 : 5 dossiers filed and 4 API filed

*As per IQVIA May'26 MAT Branded and Gx

R&D Centre Network

Genome Valley

Integrated product development

Pragathi Nagar

CoE for CNS API; KSMs; Bio Lab (Enzyme)

GPI R&D, USA

CNS Finished Dosage; Complex FD tech

Pune R&D

New technologies; KSM & backward integration


Ascelis Peptides Lab

Peptide R&D at IIT Hyderabad


Senn Chemicals AG

Peptide CDMO R&D, Switzerland

Regulatory Audit



Customer Audit



Facility	USFDA Inspection	EIR Status
GPI (Virginia)	Apr'2026	✓
Gagillapur	Aug'2024	Reinspection
GCH Packaging	Dec'2025	✓
Genome Valley	Dec'2025	✓
Bonthapally	Jun'2025	✓
Jeedimetla	Jun'2023	✓
Unit IV	Jun'2023	✓
Unit V	Apr'2024	✓

- GPI received a VAI-classified FDA EIR for its April 2026 inspection.
- Gagillapur April 2026 TGA Australia inspection closed with no critical findings.
- Czech Agency issued an EU GMP certificate for Genome Valley.
- Phased facility upgradation for quality compliance and digital transformation program across all manufacturing facilities, with capex investments of approximately Rs.260 Mn in the last one year and planned investment of Rs.750 Mn, focused on automation and digitalization initiatives within Quality operations for next two years.

10

Manufacturing
Facilities

39 Bn+

Annual FD
Dosage Capacity

39,360

API Capacity
(TPA)

441

R&D
Scientists

6

R&D
Centers

Bonthapally API: 34,560 TPA

Jeedimetla API: 4,800 TPA | PFI: 1,440 TPA,

Vizag Unit-IV - API: 380 KL PA | **Unit-V**: API-15 KL PA, Onco FD
1.1 Bn dosages

GPAK, USA 2 OTC + 1 Rx Packaging lines

Gagillapur FD: 26.8 Bn dosages | PFI: 23,200 TPA

Genome Valley FD: 10 Bn dosages

GPI Virginia, USA FD: 1.5 Bn dosages

Senn Chemicals, Switzerland Peptide CDMO

R&D Investment: ₹880 Mn (6.0% of sales) in Q1FY27 | 153 dossiers filed globally | 103 approvals (including tentative approval) | 112 DMFs across US, EU, Canada, Japan, Korea, Brazil, China



Granules' Strategy and Execution



Consistent Growth

- 6 consecutive quarters of sequential growth
- **20%** YoY sales growth to ₹53,656 Mn
- Diversified across API, PFI, FD and CDMO
- FD at **74%** of revenue
- Formulations business compounded at **20%** CAGR over FY22 to FY26, reflecting a structurally strengthening growth engine



Portfolio Upgrade

- Shifted from volume driven to value driven Complex Gx-led business model
- Complex Gx now **43%** share in FD
- Oncology and Peptide CDMO emerging as next-gen growth engines



Quality Upgradation

- Strengthening quality and compliance systems across all manufacturing sites.
- Expanding digital capabilities through MES, electronic records, and integrated laboratory systems.
- Enhancing data integrity and governance to build a more robust and sustainable compliance framework.



Margin Expansion

- Record **Gross** and **EBITDA** margins in FY26
- Gross Margin expanded by ~1507 bps, EBITDA margin expanded ~290 bps over FY22-FY26
- Complex Gx mix driving structural margin improvement



Capital Discipline

- CAPEX investment of ₹5,547 Mn was made in FY26, totaling ₹23,107 Mn cumulatively from FY22 to FY26, covering the Genome Valley 10 Bn tablet facility, MUPS facility, and packing facility in the USA
- Growth capital expenditures have been funded through cash flows from operations.

Four Decades of Strategic Evolution

Foundation

- Pioneered Paracetamol API in India; cost leadership became a durable moat
- Built Bonthapally hub – scalable platform anchoring decades of growth
- Scaled Jeedimetla API capacity for global regulated markets
- Cultivated global customer relationships anchoring predictable volumes
- Embedded a culture of disciplined execution and capital efficiency

Forward Integration

- Entered Finished Dosages – unlocking per-molecule margin expansion
- Established GPI in the US – direct access to the largest regulated market
- Gagillapur PFI facility deepened backward integration for end-to-end cost advantage
- In-house API, PFI and FD control mitigated supply risk and reduced external dependence
- Centralized quality and regulatory oversight improved compliance across regulated markets

Scale & Diversify

- Built world's largest single-site MUPS facility – a rare manufacturing moat
- Packing Facility in Virginia full US supply chain control, cutting lead times
- Revenue scale-up validated a compounding, multi-geography business model
- R&D investment accelerated transition to Complex Gx, MUPS and higher-value FD
- Enhanced FD capabilities with Additional Genome valley 10Bn Tablets capacity

Transformation

- Pivoted into high-barrier segments: Peptide CDMO and Complex Gx
- Complex Gx reached 43% of FD (from 31%) – decisive premium-margin shift
- Structurally de-risked through customer and portfolio diversification
- Deepened regulated-market filings funnel R&D and GLS scale
- Acquired Senn Chemicals – entered Peptide CDMO, adding a high-value growth vector



Complex Generics Scale-up

- CNS portfolio driving US volume
- Complex Gx share rose from 31% to 43% of FD in just one year (+1200 bps YoY in FY26)
- Controlled substances, MUPS platform; 59 complex dossiers filed; 180-day exclusivity opportunities
- Total 148 dossier filings - 97 dossiers filed & approved; 51 Filings awaiting approvals as on FY26
- Total Complex Gx dossier filings 59, 32 approved and 27 awaiting approval



Peptide CDMO Ramp

- Senn Chemicals acquired Apr 2025. Swiss-based CDMO with 60+ years in peptide synthesis
- EBITDA Breakeven achieved in Q4FY26; Ascelis Peptides subsidiary driving R&D pipeline
- TFA-free peptide chemistries for cosmetics segment; GLP-1 / peptide therapeutics market expanding rapidly



Geographic Diversification

- Evolving from a North America-centric model to a multi-region value platform, anchored in regulated markets across North America, Europe and Select ROW
- Europe and regulated ex-North America markets emerging as the next growth engines, backed by expanding dossiers, complex launches and rising CDMO engagement
- Geographic expansion aligned with portfolio complexity, enabling scalable rollout of Complex Gx, Peptides and Specialty products with high entry barrier



Capacity Expansion

- Genome Valley GLS: 10Bn dosages now is USFDA approved, Rx Products shipments started
- GLS approval increases formulation capacity by 40%; enables multisite manufacturing
- Vizag dedicated oncology OSD, Virginia US facility (1.5Bn dosages)
- FY26 capex: ₹5,547 Mn; de-risking strategy across multiple facilities



Innovation Platforms

- FY26 R&D spend 5.3% of revenue up 20% YoY
- Focus areas: CNS/ADHD, oncology, peptides, high barrier, metabolic disorders
- IIT Hyderabad R&D center boosting peptide & particle synthesis development capabilities



Oncology Pipeline

- Day 1 / Day 181 launch opportunities for high-value oncology molecules
- Active development pipeline; targeting high-barrier generics
- Dedicated oncology OSD plant in Vizag with separate API block
- Strategic pivot to high-complexity, high-margin therapeutic segments for long-term growth

Purpose

Healing lives
responsibly
through pioneering
green science

Vision

To establish ourselves as a world leader in green chemical and pharmaceutical industry by harnessing cutting-edge technologies to enhance quality of life.

Values

- 1 Challenging Limits
- 2 Futuristic Thinking
- 3 Empowering Employees
- 4 Customer Driven
- 5 Quality Everywhere
- 6 Environmental Stewardship

Sustainability at Granules : Pioneering Innovation for Complete Supply Chain

Decarbonization of Pharmaceuticals



Commitments



Ratings & Certifications



Sustainability Performance

45.7 %

Scope 1 and Scope 2
Absolute Reduction *

* Over base year FY 23



8.8 %

Scope 3
Absolute Reduction *

* Over base year FY 23



98 %

Share of Renewable
Energy of Electricity #
Including PPA & I-RECS *



93 %

Waste diverted from landfill



39 %

Of Wastewater generated
is recycled



Partner Collaboration Platforms



Our CSR Journey : Empowering Communities, Enriching Lives



OUR GOAL

Touch **1 Million**
Lives by 2030

OUR PROGRESS

4,50,000 +
Lives Positively Touched

FOCUS AREAS



Skill Development

1,700 +
trained through Pharma Pathashala
since inception from 2017



Health

15,000 +
Benefitted through Breast Cancer 85
Screening Camps, Awareness sessions Eye
Screenings to school children



Education

2,000+
Students are benefiting through
vidya Volunteers, Educational
support through NGO partners



Environment & Biodiversity

18,000 +
Native trees have been planted.
1,00,000 + Participants in Fourth Edition of
Granules Green Heartfulness Run



Investor Communication



For investor relation – Granules IR desk

Email: investorrelations@granulesindia.com

www.granulesindia.com



Ms. Payal Dave

Payal.dave@in.mpms.mufg.com

Mr. Irfan Raeen

+91 97737 78669

Irfan.raeen@in.mpms.mufg.com

www.in.mpms.mufg.com

Corporate address:

15th Floor, Granules Tower, Botanical Garden road, Kondapur, Hyderabad - 500084
CIN: L24110TG1991PLC012471

Voice: +91 40 69043500
www.granulesindia.com

thank you!



BSE 532482

NSE GRANULES

Bloomberg GRAN:IN

REUTERS GRAN:NS